Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nyxoah (Nasdaq: NYXH) announced its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec 4, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nyxoah (Nasdaq: NYXH) announced its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec 4, 2025.
The session is scheduled for 1:30 p.m. ET and will be available via a live audio webcast on the company investor relations site at investors.nyxoah.com. The presentation will cover recent corporate developments and provide management commentary to investors and analysts.
Details
News Market Reaction – NYXH
On Nov 28, the first trading day after this news, NYXH closed 2.78% above the previous close.
Data tracked by StockTitan Argus for the Nov 28 session.
Key Figures
- Conference edition
- 37th Annual
- Piper Sandler 37th Annual Healthcare Conference
- Conference date
- Dec. 4, 2025
- Date of Nyxoah fireside chat
- Chat time
- 1:30 p.m. ET
- Scheduled time of fireside chat
- Release time CET
- 10:05 p.m. CET
- Press announcement time in Mont-Saint-Guibert
- Release time ET
- 4:05 p.m. ET
- Press announcement time Eastern Time
Historical Context
-
Transparency notifications detailing changes in major shareholder voting rights.
-
Announcement of management fireside chat at Piper Sandler healthcare conference.
-
Publication of updated share capital, voting rights, and subscription rights figures.
-
Up to U.S. $77M in mixed financing to fund Genio commercialization and R&D.
-
Q3 results with revenue growth, FDA-approved launch, and significant operating loss.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
obstructive sleep apnea medical
neuromodulation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference
Mont-Saint-Guibert, Belgium – 27 November, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec. 4, 2025. The fireside chat is scheduled at 1:30 p.m. (ET) the same day via webcast.
A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at investors.nyxoah.com.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.
Contact:
Nyxoah
John Landry
Chief Financial Officer
IR@nyxoah.com
Rémi Renard
Chief Investor Relations & Corporate Communication Officer
IR@nyxoah.com
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.